CORE--ANALYTIC
核心--分析
基本信息
- 批准号:7447872
- 负责人:
- 金额:$ 20.18万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:Alzheimer&aposs disease modelAnimalsBioinformaticsBloodBrainBrain regionCatalogingCatalogsCluster AnalysisCustomDiscriminationElectronsEnsureFutureGasesGene ExpressionGenesHippocampus (Brain)Hormone AntagonistsHormonesIndividualLiquid substanceMass Spectrum AnalysisMenopauseModelingMusNumbersPathway interactionsPatternPattern RecognitionPerimenopausePharmacologic SubstancePlasmaPolymerase Chain ReactionProcessProgesteroneProteinsPurposeRNA ProcessingRadioimmunoassayRattusResearchResearch PersonnelReverse Transcriptase Polymerase Chain ReactionSamplingScienceSerumServicesSolutionsSpecimenSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationTimeTissue BankingTissue SampleTissuesTranslational ResearchUrineUterusbrain tissuecomputational chemistrydetectorhormone metabolisminhibitor/antagonistionizationmemberprofessorprogramsresearch study
项目摘要
Core C: Analytic
The Analytical Core, under the direction of Dr. Nouri Neamati, Assistant Professor of
Pharmaceutical Sciences, will process, bank, and analyze all tissues and appropriate samples for
research purposes for use in this Program Project. The tissues as well as fluid, specimens including
blood, serum, and urine will be collected where needed for individual investigators with hypothesis
driven translational research. The Analytical Core will provide the following services where
appropriate:
1) Macroarray analysis of 100 highly relevant customized genes using SuperArray platform.
2) Real-Time PCR for selected genes.
3) Mass Spectrometry including MALDI and MS/MS analysis for selected samples.
4) Progesterone and metabolite analysis by Gas Chromatograph with Mass Selective Detector
utilizing Electron Impact ionization, and 5) Quantitative analysis of progesterone and metabolites by
radioimmunoassays.
核心C:分析
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
NOURI NEAMATI其他文献
NOURI NEAMATI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('NOURI NEAMATI', 18)}}的其他基金
Preclinical Development of First-in-Class NDUFS7 Antagonists for the Treatment of Pancreatic Cancer
用于治疗胰腺癌的一流 NDUFS7 拮抗剂的临床前开发
- 批准号:
10684845 - 财政年份:2022
- 资助金额:
$ 20.18万 - 项目类别:
Preclinical Development of First-in-Class GSTO1 Degraders for Colorectal Cancer
首创的结直肠癌 GSTO1 降解剂的临床前开发
- 批准号:
10675586 - 财政年份:2022
- 资助金额:
$ 20.18万 - 项目类别:
gp130 as a novel therapeutic target in ovarian cancer
gp130作为卵巢癌的新治疗靶点
- 批准号:
8797755 - 财政年份:2015
- 资助金额:
$ 20.18万 - 项目类别:
gp130 as a novel therapeutic target in ovarian cancer
gp130作为卵巢癌的新治疗靶点
- 批准号:
8994723 - 财政年份:2015
- 资助金额:
$ 20.18万 - 项目类别:
gp130 as a novel therapeutic target in ovarian cancer
gp130作为卵巢癌的新治疗靶点
- 批准号:
9903250 - 财政年份:2015
- 资助金额:
$ 20.18万 - 项目类别:
High Throughput Screen for Myotonic Dystrophy Type 1
1 型强直性肌营养不良的高通量筛查
- 批准号:
8209483 - 财政年份:2011
- 资助金额:
$ 20.18万 - 项目类别:
相似海外基金
Elucidation of mucosal healing mechanisms through the construction of a human Crohn 's disease model
通过构建人类克罗恩病模型阐明粘膜愈合机制
- 批准号:
20K08378 - 财政年份:2020
- 资助金额:
$ 20.18万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




